United States - English - NLM (National Library of Medicine)

american health packaging - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol reduces serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology , contraindications , warnings and precautions ). allopurinol is indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol reduces serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings and precautions). allopurinol is indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present. the management

Ireland - English - HPRA (Health Products Regulatory Authority)

silver pharma s.l. - mercaptopurine - tablet - 50 milligram(s) - mercaptopurine

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - mercaptopurine monohydrate, quantity: 50 mg - tablet - excipient ingredients: pregelatinised maize starch; stearic acid; maize starch; magnesium stearate; lactose - treatment of acute leukaemia. it is of value in remission induction and is particularly indicated for maintenance therapy in acute lymphoblastic leukaemia and acute myelogenous leukaemia.,mercaptopurine-link is also used in the treatment of chronic granulocytic leukaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - allopurinol -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - allopurinol -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - allopurinol - oral tablet - 300mg

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - allopurinol - tablet - allopurinol 300 mg - antigout preparations

Malta - English - Medicines Authority

crescent pharma international limited 260, triq san albert, gzira gzr 1150, malta - allopurinol - tablet - allopurinol 300 mg - antigout preparations

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - allopurinol 100mg;   - tablet - 100 mg - active: allopurinol 100mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.